MA54825A - Modulateurs de gpr35 - Google Patents

Modulateurs de gpr35

Info

Publication number
MA54825A
MA54825A MA054825A MA54825A MA54825A MA 54825 A MA54825 A MA 54825A MA 054825 A MA054825 A MA 054825A MA 54825 A MA54825 A MA 54825A MA 54825 A MA54825 A MA 54825A
Authority
MA
Morocco
Prior art keywords
gpr35
modulators
gpr35 modulators
Prior art date
Application number
MA054825A
Other languages
English (en)
French (fr)
Inventor
Robert Higuchi
Original Assignee
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Biosciences Inc filed Critical Prometheus Biosciences Inc
Publication of MA54825A publication Critical patent/MA54825A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA054825A 2019-01-24 2020-01-23 Modulateurs de gpr35 MA54825A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US201962928223P 2019-10-30 2019-10-30

Publications (1)

Publication Number Publication Date
MA54825A true MA54825A (fr) 2021-12-01

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054825A MA54825A (fr) 2019-01-24 2020-01-23 Modulateurs de gpr35

Country Status (13)

Country Link
US (2) US11053251B2 (enExample)
EP (1) EP3914256B1 (enExample)
JP (1) JP7588077B2 (enExample)
KR (1) KR102863894B1 (enExample)
CN (1) CN113631168B (enExample)
AU (1) AU2020210930B2 (enExample)
BR (1) BR112021014566A2 (enExample)
CA (1) CA3127786A1 (enExample)
IL (1) IL285074B2 (enExample)
MA (1) MA54825A (enExample)
MX (1) MX2021008941A (enExample)
TW (1) TWI845600B (enExample)
WO (1) WO2020154492A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
WO2022020617A1 (en) * 2020-07-23 2022-01-27 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
GB202303387D0 (en) * 2023-03-08 2023-04-19 Thirtyfivebio Ltd Compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
FR2845993B1 (fr) 2002-10-16 2005-02-11 Univ Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
CA2558721A1 (en) * 2004-02-27 2005-09-15 Pfizer Inc. Screening method for emulators of neural activity and digestive system using gpr35
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
WO2012167053A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
US20150273088A1 (en) 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
US10519373B2 (en) 2014-06-29 2019-12-31 Profile Products, L.L.C. Bark and wood fiber growing medium
US10626180B2 (en) 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
TW202014217A (zh) * 2018-04-27 2020-04-16 美國錫安山醫學中心 標靶gpr35以治療發炎性腸病症的組合物及方法
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
WO2020163713A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
MA54903A (fr) 2019-02-08 2021-12-15 Cedars Sinai Medical Center Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
WO2021108694A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
WO2022020617A1 (en) 2020-07-23 2022-01-27 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
JP2023551602A (ja) 2020-11-13 2023-12-08 プロメテウス バイオサイエンシーズ,インク. Tl1aを標的とする炎症性疾患の治療のための方法、システム、およびキット
WO2022140283A1 (en) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith

Also Published As

Publication number Publication date
CN113631168A (zh) 2021-11-09
JP7588077B2 (ja) 2024-11-21
AU2020210930B2 (en) 2025-08-14
KR102863894B1 (ko) 2025-09-23
TW202043234A (zh) 2020-12-01
EP3914256A4 (en) 2022-09-28
EP3914256B1 (en) 2024-05-29
IL285074B1 (en) 2024-08-01
EP3914256A1 (en) 2021-12-01
CN113631168B (zh) 2024-11-19
JP2022518523A (ja) 2022-03-15
US11053251B2 (en) 2021-07-06
US11773101B2 (en) 2023-10-03
CA3127786A1 (en) 2020-07-30
AU2020210930A1 (en) 2021-09-09
IL285074B2 (en) 2024-12-01
IL285074A (en) 2021-09-30
US20210380590A1 (en) 2021-12-09
KR20210119485A (ko) 2021-10-05
MX2021008941A (es) 2021-10-13
US20200239476A1 (en) 2020-07-30
TWI845600B (zh) 2024-06-21
WO2020154492A1 (en) 2020-07-30
BR112021014566A2 (pt) 2022-01-04

Similar Documents

Publication Publication Date Title
DK3743406T3 (da) Tmem16a modulatorer
ZA202007307B (en) Nlrp3 modulators
MA50014A (fr) Modulateurs de k-ras
EP3861130A4 (en) GENETIC MODULATORS
MA55328A (fr) Modulateurs de ror-gamma
EP3684368A4 (en) SELECTIVE P2X3 MODULATORS
IL281812A (en) Monoacylglycerol lipase modulators
HUE062866T2 (hu) TREX-1 modulátorok
GB2596231B (en) Modulators
EP3899024A4 (en) Modulators of hsd17b13 expression
MA53943A (fr) Modulateurs de ror-gamma
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
EP3675849A4 (en) TETRAHYDROCANNABINOL MODULATORS
IL285074A (en) Gpr35 modulators
EP3853365A4 (en) MODULATORS OF PNPLA3 EXPRESSION
EP3601569A4 (en) PCSK9 EXPRESSION MODULATORS
DK3749669T3 (da) Ahr-modulatorer
MA53722A (fr) Modulateurs de la monoacylglycérol lipase
IL285772A (en) Treatment with p2x3 modulators
EP3694528A4 (en) MTORC1 MODULATORS
EP3374386C0 (en) PROTEASE-ACTIVATED RECEPTOR TYPE 2 MODULATORS
GB201704739D0 (en) Optical modulator
EP4192957A4 (en) Trpml modulators
EP3532062A4 (en) ROR GAMMA MODULATORS
EP4025957C0 (en) ELECTRO-OPTIC MODULATOR